scholarly journals Is it important to analyse serum liver enzymes in patients with established metabolic syndrome? A Pilot study to tie the knot

2017 ◽  
Vol 8 (3) ◽  
pp. 35-40
Author(s):  
Saumyajit Maiti ◽  
Arun Kumar
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Biochemical Parameters ◽  
Elevated Serum ◽  
Treatment Modalities ◽  
P Value ◽  
Additional Risk Factor ◽  
Atherosclerotic Vascular Disease ◽  
Area Of Concern ◽  
Female Subjects

Background: Metabolic Syndrome (MetS) is one of theemerging health problems which is the major area of concern as it is not only a potential risk factor for some many diseases but it also affecting globally. It is a common multi-factorial disorder of metabolic derangements and prominent etiological factors for the development and progression of atherosclerotic vascular disease and type 2 diabetes. The relation between elevated serum gamma-glutamyltranferase and metabolic syndrome, however, have been not well explored in a developing country like India. Aims and Objectives: The current study was designed to estimate the levels of alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT) in metabolic syndrome patients with age-sex matched healthy controls. Furthermore the relation of liver function status with the various biochemical parameters of metabolic syndrome was explored.Materials and Methods: In this present only patients of metabolic syndrome were selected based on inclusion and exclusion criteria of selecting cases. All the biochemical parameters were analysed using standard methods. Data collected were analysed using Statistical Package for the Social Sciences (version 20.0).  P value (p<0.05) was considered to be significant.Results: Of the 200 cases and controlsselected, the differences in serum GGT (p<0.001) and ALT (p=0.048) were statistically significant. In case of male subjects,study and controls groups were compared only for serum GGT level (p=0.032) and in case of female subjects, studyand controls were compared for serum ALT (p=0.027) and serum GGT level (p<0.001)and the differences were found to be highly significant. When male and female subjects of study group were compared, significant differences were observed in their serum ALT and GGT levels.Conclusion: Patients suspected of metabolic syndrome must also get their liver profile enzymes analysed as liver functionis also affected with metabolic syndrome and it could be an additional risk factor additive of metabolic syndrome. Early detection and management can be preventive and can have a better treatment modalities is managing patients with metabolic syndrome. It not only prevent disease progression but also prevents additional cost burden beard by the patients.Asian Journal of Medical Sciences Vol.8(3) 2017 35-40

scholarly journals Exposure to Airborne Particulate Matter: An Additional Risk Factor for Metabolic Syndrome in Saudi Arabia

2015 ◽  
Vol 26 (2) ◽  
pp. 63-73
Author(s):  
Mansour A. Alghamdi Mansour A. Alghamdi
Keyword(s):  
Metabolic Syndrome ◽  
Saudi Arabia ◽  
Risk Factor ◽  
Particulate Matter ◽  
Elemental Composition ◽  
Life Style ◽  
Airborne Particulate Matter ◽  
Additional Risk Factor ◽  
Airborne Particulate ◽  
Additional Risk

. Metabolic syndrome is a serious problem in Saudi Arabia. It has been attributed mainly to life style. Exposure to airborne particulate matter is a subject of concern in Jeddah. The present study aimed to find a possible association of metabolic syndrome prevalence with levels of particulate matter and their elemental constituents. The study was conducted in two districts of Jeddah, Al Nuzlah and Al Rehab. PM10 and PM2.5 were measured in each district as well as their elemental composition. Metabolic syndrome was defined by the presence of three components: hyperglycemia, hypertension and obesity. Al Nuzlah district showed higher prevalence of metabolic syndrome, together with higher levels of PM2.5, nickel and cadmium. It can be concluded that exposure to particulate matter may be considered as an additional risk factor for metabolic syndrome.

scholarly journals Elevated Serum Advanced Glycation Endproducts in Obese Indicate Risk for the Metabolic Syndrome: A Link Between Healthy and Unhealthy Obesity?

2015 ◽  
Vol 100 (5) ◽  
pp. 1957-1966 ◽  
Author(s):  
Jaime Uribarri ◽  
Weijing Cai ◽  
Mark Woodward ◽  
Elizabeth Tripp ◽  
Laurie Goldberg ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Risk Factor ◽  
Fat Mass ◽  
Advanced Glycation Endproducts ◽  
Elevated Serum ◽  
Cross Sectional Study ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
The Metabolic Syndrome

Abstract Context: Although obesity can predispose to the metabolic syndrome (MS), diabetes, and cardiovascular disease, not all obese subjects develop MS, hence the need for new indicators of risk for this syndrome. Advanced glycation end products (AGEs) correlate with factors involved in the MS, including inflammation and insulin resistance (IR). Because AGEs can be derived from food and are modifiable, it is important to determine whether they are a risk factor for MS. Objective: The objective of this study was to assess the association of endogenous and exogenous AGEs with MS criteria. Design: The following data were collected in a cross-sectional study of subjects with and without the MS: serum AGEs (sAGEs) and mononuclear cell AGEs, metabolites, pro- and antiinflammatory markers, body fat mass measures, including abdominal magnetic resonance imaging, and caloric and dietary AGE (dAGE) consumption. Setting: The study was conducted in the general community. Participants: Participants included 130 MS and 139 non-MS subjects of both sexes, older than 50 years. Results: sAGEs (ϵN-carboxymethyllysine, methylglyoxal) were markedly elevated in obese persons with more than one other MS criteria but not in obese without MS criteria. sAGEs directly correlated with markers of IR (HOMA) and inflammation (leptin, TNFα, RAGE) and inversely with innate defenses (SIRT1, AGE receptor 1 [AGER1], glyoxalase-I, adiponectin). sAGEs correlated with dAGEs but not with calories, nutrient consumption, or fat mass measures. Consumption of dAGE, but not of calories, was markedly higher in MS than in non-MS. Conclusion: High sAGEs, a modifiable risk factor for IR, may indicate risk for the MS, type 2 diabetes, and cardiovascular disease. High dietary AGE consumption and serum AGE levels may link healthy obesity to at-risk obesity.

scholarly journals Is hysterectomy a risk factor for urinary incontinence?

2019 ◽  
Vol 8 (4) ◽  
pp. 1260
Author(s):  
Maria C. Alexander ◽  
Vaibhav Londhe ◽  
Emily D. Ebenezer ◽  
Aruna N. Kekre ◽  
Visalakshi Jeyaseelan
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Urinary Incontinence ◽  
Tamil Nadu ◽  
Categorical Variables ◽  
P Value ◽  
Natural Menopause ◽  
Menopausal Women ◽  
Surgical Menopause ◽  
Post Menopausal

Background: Hysterectomy is the most common gynecological surgery performed. There are few studies evaluating hysterectomy as a risk factor for urinary incontinence. If hysterectomy is found to be a risk factor for developing urinary incontinence, women undergoing hysterectomy can be well informed prior to the procedure regarding the same. The objective of the present study was to study the prevalence of urinary incontinence in post-menopausal women and its relationship to hysterectomy. To evaluate the association of metabolic syndrome, to urinary incontinence.Methods: This study was a prospective cohort study done in Christian Medical College and Hospital, Vellore, Tamil Nadu between December 2016- December 2017. Postmenopausal women both with natural and surgical menopause, were enrolled into the study after an informed consent. The UDI-6 questionnaire was used to assess urinary incontinence. The categorical variables were presented using frequencies and percentages. The comparison of categorical variables was done using Fisher's exact test. The odds ratio and confidence interval were calculated for the prevalence. P value < 0.05 was considered to be statistically significant.Results: A total of 600 women were enrolled into the study with 300 women having attained natural menopause and 300 women with a surgical menopause. The prevalence of urinary incontinence among these post-menopausal women was 46.24%. The prevalence of urinary incontinence amongst the women with natural menopause was 47.3% and amongst the women with surgical menopause was 45% (p = 0.566). Women with metabolic syndrome suffered from urinary incontinence more than their counterparts without metabolic syndrome (55.8% vs. 36%, p <0.0001).Conclusions: The prevalence of urinary incontinence in the natural menopause and surgical menopause groups was similar, thus proving that hysterectomy is not a risk factor for developing urinary incontinence. However, metabolic syndrome was found to be associated with urinary incontinence. 

scholarly journals Comparison of metformin and N-acetylcysteine on metabolic parameters in women with polycystic ovarian syndrome

2017 ◽  
Vol 6 (7) ◽  
pp. 3076 ◽  
Author(s):  
Hina Ali ◽  
Gita Radhakrishnan ◽  
Alpana Singh
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Side Effects ◽  
Reproductive Age ◽  
Treatment Modalities ◽  
Term Therapy ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Common Disease ◽  
Study Results

Background: Polycystic ovary syndrome (PCOS) is a common disease that affects up to 10% of women of reproductive age, in which hyperandrogenism (HA), enlarged cystic ovaries, and chronic anovulation often co-exist with obesity, dyslipidemia and insulin resistance (IR). There is a need for an alternative to metformin with minimal side effects to improve insulin sensitivity and correct dyslipidemia in PCOS patients.Methods: It was a prospective, Randomized controlled clinical trial. 116 PCOS patients, 58 each in two groups received either Metformin 500 mg TDS or N-acetylcysteine (NAC) 600 mg TDS for 3 months. Clinical and biochemical parameters contributing to metabolic syndrome (MS) and insulin resistance (fasting blood sugar (FBS), fasting insulin (FI), FBS:FI, HOMA-IR and QUICKI) were assessed at the start and end of the study. Results were compared between the two groups.Results: Both treatment modalities resulted in a significant reduction in number of cases with IR (p=0.001) and MS. Fasting hyperinsulinemia improved in 15 % (p=0.12) and 30% (p=0.001) of patients while 12% (p=0.23) and 18% (p=0.049) improvement was seen in FBS:FI in MET and NAC group respectively. Similarly, improvement in HOMA-IR was 12% (p=0.30) and 32% (p=0.001) in MET and NAC group which is significant with NAC. QUICKI and impaired glucose tolerance showed significant improvement in both the groups with a p-value of 0.04 and 0.006, 0.035 and 0.046 respectively. Significant reduction was seen in triglycerides (p=0.048) in NAC group.Conclusions: NAC is equally efficacious as metformin in improving parameters of insulin resistance and metabolic syndrome with minimal occasional side effects ensuring better compliance for a long-term therapy.

High prevalence of elevated serum liver enzymes in Chinese children suggests metabolic syndrome as a common risk factor

2020 ◽  
Vol 56 (10) ◽  
pp. 1590-1596
Author(s):  
Jinling Wang ◽  
Hui‐Qi Qu ◽  
Ke Huang ◽  
Wei Wu ◽  
Chunlin Wang ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Liver Enzymes ◽  
Elevated Serum ◽  
Chinese Children ◽  
Common Risk Factor ◽  
High Prevalence

Is Hyperhomocysteinemia an Additional Risk Factor of the Metabolic Syndrome?

2006 ◽  
Vol 4 (3) ◽  
pp. 185-195 ◽  
Author(s):  
J.-M. Garcin ◽  
S. Cremades ◽  
C. Garcia-Hejl ◽  
L. Bordier ◽  
O. Dupuy ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Additional Risk Factor ◽  
Additional Risk ◽  
The Metabolic Syndrome

scholarly journals Increased aldosterone in patients with metabolic syndrome; an additional risk factor

2013 ◽  
Vol 2 (1) ◽  
pp. 17
Author(s):  
Mohamed Abdou ◽  
Mohamed Sherif AbdElGawad ◽  
Sahar AlSayed Mohamed
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Additional Risk Factor ◽  
Additional Risk

Ferritin level is associated with metabolic syndrome and elevated alanine aminotransferase in children and adolescents

2016 ◽  
Vol 29 (12) ◽  
Author(s):  
Kyung Hee Yi ◽  
Jin Soon Hwang ◽  
Se Won Lim ◽  
Jun Ah Lee ◽  
Dong Ho Kim ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Children And Adolescents ◽  
Serum Ferritin ◽  
Alanine Aminotransferase ◽  
Ferritin Level ◽  
Elevated Serum ◽  
Range Limits ◽  
P Value ◽  
Health And Nutrition ◽  
Independent Association

Abstract Background: The aim of the study was to investigate the association among elevated serum ferritin, metabolic syndrome (MetS) and ‘elevated alanine aminotransferase (ALT) levels beyond healthy-range limits’ in children and adolescents. Methods: We analyzed data from 4855 subjects (2579 male) aged 10–19 who participated in the Korea National Health and Nutrition Examination Survey (KNHANES) (2007–2012). Results: The prevalence of MetS and ‘elevated ALT’ tended to increase with an increase in the serum ferritin quartile (p-value for trend: all <0.05). The odds ratios (ORs) for MetS in serum ferritin quartile-Q4 compared to ferritin quartile-Q1 was 1.59 (1.01, 2.55) in females after adjusting for age, body mass index (BMI), and insulin resistance. The ORs for ‘elevated ALT’ in ferritin quartile-Q4 compared to ferritin quartile-Q1 were 4.45 (2.18, 9.10) in male and 3.10 (1.70, 5.66) in female subjects after adjusting for other covariates. Conclusions: The independent association between elevated serum ferritin and MetS (or ‘elevated ALT’) begins in children and adolescents.

Standardized comparison of cardiovascular risk factors prevalence in Spanish women and men living with HIV and in the general population

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
A Camps-Vilaro ◽  
S Perez-Fernandez ◽  
R Teira ◽  
V Estrada ◽  
P Domingo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Risk Factor ◽  
General Population ◽  
Density Lipoprotein ◽  
P Value ◽  
People Living With Hiv ◽  
General Population Cohort ◽  
History Of ◽  
Living With Hiv

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Spain’s Ministry of Science and Innovation (Madrid, Spain), co-financed with European Union European Regional Development Funds –ERDF- [CIBERCV CB16/11/00229]; the Health Department of the Generalitat de Catalunya (Barcelona, Spain) through the Agència de Gestió d’Ajuts Universitaris de Recerca de Catalunya (AGAUR) (Barcelona, Spain) [2017SGR222]. OnBehalf DARIOS and VACH investigators Background People living with HIV (PLWH) have an increased risk of cardiovascular (CV) disease, likely due to a higher prevalence of CV risk factors. We compared age-standardized prevalence and management of CV risk factors in PLWH to that of general population in Spain. Methods Blood pressure, lipid, glucose and anthropometric profile were cross-sectionally compared along with treatment of hypertension, dyslipidemia, and diabetes in a general population cohort and a PLWH cohort. Prevalence rates were standardized by the direct method by 10-year age groups in European standard populations by gender.  Results We included 39,598 individuals aged 35 to 74 years: 28,360 from the general population cohort and 11,238 from the PLWH cohort. Compared to general population, PLWH had a higher concentration of triglycerides (&gt;35mg/dL in women and &gt;26mg/dL in men), and a higher prevalence of metabolic syndrome (&gt;10% and &gt;7.8%) and diabetes (&gt;8.5% and &gt;5.3%) (Table). The proportion of treated diabetes, dyslipidemia, and hypertension were up to 3-fold lower in both women and men living with HIV than in general population (Table). Conclusions Lipid, gluco-metabolic profiles were significantly worse in PLWH compared to general population. In addition, PLWH were less often treated for diagnosed diabetes, dyslipidemia, and hypertension. CV risk factor standardized prevalence Cardiovascular risk factor WOMEN MEN General population People living with HIV p-Value General population People living with HIV p-Value N = 15,159 N = 2,171 N = 13,201 N = 9,067 Hypertension, % 27.4 (26.7 - 28.0) 24.8 (21.6 - 28.1) 0.136 29.0 (28.2 - 29.7) 22.9 (21.4 - 24.4) &lt;0.001 Treated hypertension, % a 62.7 (60.7 - 64.7) 18.9 (13.5 - 24.4) &lt;0.001 59.3 (57.5 - 61.1) 24.1 (21.0 - 27.1) &lt;0.001 Triglycerides, mg/dL b 99 (99 - 100) 134 (134 - 148) &lt;0.001 122 (121 - 122) 148 (148 - 164) &lt;0.001 Total cholesterol, mg/dL 214 (213 - 215) 207 (199 - 215) 0.111 214 (213 - 216) 195 (191 - 198) &lt;0.001 Treated dyslipidaemia, % c 14.0 (13.5 - 14.6) 7.80 (5.60 - 10.0) &lt;0.001 15.1 (14.5 - 15.7) 7.8 (6.8 - 8.7) &lt;0.001 Glucose, mg/dL 97 (96 - 97) 103 (98 - 107) 0.007 104 (103 - 105) 106 (104 - 109) 0.122 Diabetes, % 10.6 (10.1 - 11.1) 19.1 (16.0 - 22.1) &lt;0.001 15.4 (14.8 - 16.0) 20.7 (19.2 - 22.2) &lt;0.001 Treated diabetes, % d 34.4 (31.5 - 37.2) 12.8 (8.00 - 17.5) &lt;0.001 40.0 (37.1 - 42.9) 16.6 (13.9 - 19.3) &lt;0.001 Metabolic Syndrome, % 20.5 (19.8 - 21.1) 31.1 (25.8 - 36.4) &lt;0.001 27.9 (27.1 - 28.7) 35.7 (33.1 - 38.2) &lt;0.001 Values are expressed as mean (95% confidence interval). a Among patients with history of hypertension. b Mean (95% confidence interval) were obtained with log-transformed values. c Among all cohort participants. d Among patients with history of diabetes. HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol

Sign in / Sign up

Export Citation Format

Share Document